Skip to main content

Biohaven Ltd

For the period ended Sep 30, 2024. Filed Nov 12, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 12, 2024

BHVN$15.11-0.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Operating expenses:
Research and development$157,607$95,517$628,398$238,468
General and administrative20,56115,03066,78243,872
Total operating expenses178,168110,547695,180282,340
Loss from operations(178,168)(110,547)(695,180)(282,340)
Other income, net17,8054,68636,28818,757
Loss before (benefit) provision for income taxes(160,363)(105,861)(658,892)(263,583)
(Benefit) provision for income taxes(59)(3,287)687(171)
Net loss$(160,304)$(102,574)$(659,579)$(263,412)
Net loss per share — basic and diluted$(1.70)$(1.50)$(7.50)$(3.86)
Weighted average common shares outstanding—basic and diluted94,372,15968,320,12587,936,92368,258,757
Comprehensive loss:
Net loss$(160,304)$(102,574)$(659,579)$(263,412)
Other comprehensive income (loss), net of tax218138205(126)
Comprehensive loss$(160,086)$(102,436)$(659,374)$(263,538)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.